Geode Capital Management LLC increased its position in GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) by 3.1% during the 4th quarter, Holdings Channel reports. The firm owned 504,567 shares of the company’s stock after acquiring an additional 15,170 shares during the quarter. Geode Capital Management LLC’s holdings in GeneDx were worth $65,635,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of WGS. Royal Bank of Canada grew its stake in GeneDx by 30.2% in the first quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock worth $2,611,000 after purchasing an additional 6,840 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in GeneDx by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock worth $677,000 after purchasing an additional 453 shares in the last quarter. NewEdge Advisors LLC grew its stake in GeneDx by 270,700.0% in the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock worth $240,000 after purchasing an additional 2,707 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in GeneDx by 67.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock worth $2,500,000 after purchasing an additional 11,375 shares in the last quarter. Finally, Cetera Investment Advisers bought a new position in GeneDx in the second quarter worth approximately $249,000. Institutional investors own 61.72% of the company’s stock.
GeneDx Stock Down 0.8%
Shares of NASDAQ WGS opened at $51.80 on Tuesday. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $1.54 billion, a PE ratio of -19.33 and a beta of 1.96. The stock’s fifty day simple moving average is $55.25 and its two-hundred day simple moving average is $92.12. GeneDx Holdings Corp. has a 12-month low of $32.21 and a 12-month high of $170.87.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on WGS. BTIG Research dropped their price objective on GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Guggenheim dropped their price objective on GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Wells Fargo & Company reissued an “overweight” rating and issued a $75.00 price objective (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Wall Street Zen cut GeneDx from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings cut GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and an average price target of $96.43.
Read Our Latest Research Report on GeneDx
Insider Buying and Selling at GeneDx
In other GeneDx news, Director Casdin Capital, Llc acquired 50,000 shares of the stock in a transaction dated Friday, June 5th. The stock was purchased at an average price of $52.86 per share, with a total value of $2,643,000.00. Following the transaction, the director directly owned 3,707,164 shares of the company’s stock, valued at $195,960,689.04. This trade represents a 1.37% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Keith A. Meister acquired 46,273 shares of the stock in a transaction dated Friday, May 15th. The stock was acquired at an average cost of $38.91 per share, with a total value of $1,800,482.43. Following the transaction, the director directly owned 4,784,570 shares in the company, valued at approximately $186,167,618.70. This represents a 0.98% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 2,256,420 shares of company stock worth $93,144,340 and have sold 72,382 shares worth $4,889,473. 29.60% of the stock is currently owned by company insiders.
Trending Headlines about GeneDx
Here are the key news stories impacting GeneDx this week:
- Positive Sentiment: Director Casdin Capital bought 150,000 shares at an average price of $56.44, a sizable insider purchase that may signal management/board confidence in GeneDx’s long-term outlook. SEC filing
- Positive Sentiment: Casdin Capital also reported another purchase of 50,000 shares at $52.86, reinforcing the recent insider accumulation trend. SEC filing
- Neutral Sentiment: Analyst coverage remains constructive overall, with GeneDx receiving an average rating of “Moderate Buy,” which may help support the stock over time. Analyst rating update
- Negative Sentiment: Multiple law firms announced or reminded investors about a securities class-action lawsuit against GeneDx, increasing legal overhang and uncertainty for shareholders. Class action announcement
- Negative Sentiment: The litigation centers on alleged investor harm tied to GeneDx’s prior disclosures and a sharp post-earnings selloff, keeping attention on operational and disclosure risks. Litigation article
About GeneDx
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Featured Articles
- Five stocks we like better than GeneDx
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS – Free Report).
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.
